Cancer drug development in China: Recent advances and future challenges

Drug Discovery Today

Volumn 20, Issue 6, 2015, Pages 766-771

  Wu, Yi Long ^a   Zhang, Helena ^b   Yang, Yumei ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GENERIC DRUG; ICOTINIB; OXALIPLATIN; VASCULOTROPIN RECEPTOR;

ARTICLE; AUTHORITY; CANCER PROGNOSIS; CANCER SURVIVAL; CASE STUDY; CHINA; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; ETHNIC DIFFERENCE; EVIDENCE BASED PRACTICE; EXPERIMENTAL THERAPY; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RESOURCE; GENOTYPE; GOVERNMENT; HUMAN; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERCEPTION; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVAL RATE; TUMOR GROWTH; ANIMAL; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG DEVELOPMENT; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; FORECASTING; MASS COMMUNICATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ONCOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DIFFUSION OF INNOVATION; DRUG DISCOVERY; FORECASTING; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84934909091     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.11.005     Document Type: Review

References (29)

1. Battelle (2013) 2014 Global R&D Funding Forecast. Batelle
2. Globocan (2012) Estimated Cancer Incidence, Mortality and Prevalence Worldwide. Globocan
3. Qi, J. et al. (2011) Innovative drug R&D in China. Nat. Rev. Drug Discov. 10, 5
4. Lux Research (2013) Mapping the Chinese Biomedical R&D Landscape. Lux Research
5. Mok, T.S. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957
6. Wu, Y. et al. (2013) Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial. Lancet Oncol. 14, 777-786
7. Wu, Y. and Zhou, Q. (2012) Clinical trials and biomarker research on lung cancer in China. Expert Opin. Ther. Targets 16 (Suppl 1), S45-S50
8. Zhou, C. et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742
9. Zhang, L. et al. (2012) Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 13, 466-475
10. Shi, Y. et al. (2013) Icotinib versus gefitinib in previously treated advanced nonsmall-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 noninferiority trial. Lancet Oncol. 14, 953-961
11. Zhao, Q. et al. (2011) Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 73, 195-202
12. Wang, H.P. et al. (2011) Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin. Med. J. 124, 1933-1938
13. Ruan, C.J. et al. (2012) Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. Eur. J. Clin. Pharmacol. 68, 1677-1680
14. Gu, A. et al. (2013) Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin. J. Cancer Res. 25, 90-94
15. Chen, X. et al. (2013) Discussion and case analysis of clinical development strategy of small-molecule targeted anti-cancer drugs. Chin. J. New Drugs 22, 269-273
16. Chen, P.J. et al. (2010) Issues and controversies of hepatocellular carcinomatargeted therapy clinical trials in Asia: experts' opinion. Liver Int. 30, 1438-1472
17. Qin, S. et al. (2010) Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asian. J. Clin. Oncol. 31, 3501-3508
18. Zhu, X. and Li, J. (2010) Gastric carcinoma in China: current status and future perspectives. Oncol. Lett. 1, 407-412 (Review)
19. Li, J. et al. (2013) Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-Arm, phase II trial. J. Clin. Oncol. 31, 3219-3225
20. Qin, S. et al. (2014) Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 32, 5s
21. Chen, X.Y. et al. (2010) Systematic review and analysis of national chemical antitumor Drugs application and review, 2005-2010. China Pharm. J. 45, 1781-1785
22. China Food and Drug Administration (2013) 2012 China Drug Review Annual Report. CFDA
23. China Food and Drug Administration (2014) 2013 China Drug Review Annual Report. CFDA
24. Yin, J. et al. (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 7, e38150
25. Gao, Y. et al. (2014) Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102
26. Wei, Q. et al. (2014) Genome-wide association study identifies three susceptibility loci for laryngeal squamous cell carcinoma in the Chinese population. Nat. Genet. 46, 1110-1114
27. Wang, L. et al. (2010) Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat. Genet. 42, 759-763
28. Xue, C. et al. (2012) National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 77, 371-375
29. Zhou, Q. et al. (2014) A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32, 5s